Susan Shiff
Director/Board Member bij CARA THERAPEUTICS, INC.
Vermogen: 46 809 $ op 31-03-2024
Profiel
Susan Patricia Shiff is an Independent Director at CARA Therapeutics, Inc. She is also a Director at Merck Global Health Innovation Fund LLC, Synthace Ltd., and a Trustee at New Jersey Symphony Orchestra.
Previously, she served as a Senior Vice President at Merck & Co., Inc. from 2014 to 2021.
She also held positions as a Vice President at Pfizer Inc. and Teva Pharmaceutics.
In addition, she was the President of Ontada LLC from 2021 to 2023.
Dr. Shiff holds a doctorate degree from the University of California, Los Angeles and an MBA from Cornell University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
CARA THERAPEUTICS INC
0.09% | 01-06-2023 | 51 438 ( 0.09% ) | 46 809 $ | 31-03-2024 |
Actieve functies van Susan Shiff
| Bedrijven | Functie | Begin |
|---|---|---|
| CARA THERAPEUTICS, INC. | Director/Board Member | 26-06-2020 |
Synthace Ltd.
 Synthace Ltd. Packaged SoftwareTechnology Services Synthace Ltd. produces bio-based chemical and biological products through synthetic biology. It is a synthetic biology company with a platform of technologies for the rapid engineering and optimization of novel biological production systems. The bioengineering platform is broadly applicable across multiple industry sectors, including the production of specialty chemicals from renewable feed stocks using efficient and sustainable processes. The company was founded by Sean Ward and Markus Christian Gershater in January 2011 and is headquartered in, London, the United Kingdom. | Director/Board Member | 05-06-2018 |
Merck Global Health Innovation Fund LLC
 Merck Global Health Innovation Fund LLC Investment ManagersFinance Merck Global Health Innovation Fund LLC invests in companies located across the globe with focus on North America and Europe. The fund focuses on companies operating in the fields of healthcare services. It provides financing for early stage and growth stage capital requirements with an investment size of USD 5 - 10 million. | Director/Board Member | - |
| New Jersey Symphony Orchestra | Director/Board Member | - |
Eerdere bekende functies van Susan Shiff
| Bedrijven | Functie | Einde |
|---|---|---|
| Ontada | President | 01-07-2023 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01-03-2021 |
| Teva Pharmaceutics | Corporate Officer/Principal | - |
| PFIZER, INC. | Corporate Officer/Principal | - |
Opleiding van Susan Shiff
| University of California, Los Angeles | Doctorate Degree |
| Cornell University | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| CARA THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
| New Jersey Symphony Orchestra | |
| Teva Pharmaceutics | |
Merck Global Health Innovation Fund LLC
Merck Global Health Innovation Fund LLC Investment ManagersFinance Merck Global Health Innovation Fund LLC invests in companies located across the globe with focus on North America and Europe. The fund focuses on companies operating in the fields of healthcare services. It provides financing for early stage and growth stage capital requirements with an investment size of USD 5 - 10 million. | Finance |
Synthace Ltd.
Synthace Ltd. Packaged SoftwareTechnology Services Synthace Ltd. produces bio-based chemical and biological products through synthetic biology. It is a synthetic biology company with a platform of technologies for the rapid engineering and optimization of novel biological production systems. The bioengineering platform is broadly applicable across multiple industry sectors, including the production of specialty chemicals from renewable feed stocks using efficient and sustainable processes. The company was founded by Sean Ward and Markus Christian Gershater in January 2011 and is headquartered in, London, the United Kingdom. | Technology Services |
| Ontada |
